Therapy Areas: Diabetes
BD Expands Offerings for Simultaneous RNA, Protein Expression Analysis
30 July 2018 - - Franklin Lakes, New Jersey-based global medical technology company Becton, Dickinson and Company (BD; NYSE: BDX) has launched the BD AbSeq assay to analyze protein expression at the single-cell level using high-throughput sequencing, the company said.
The assay brings together high-quality antibodies from the BD Pharmingen portfolio with oligonucleotides, allowing researchers to perform single-cell protein analysis on the BD Rhapsody single-cell analysis system.
When used together, these research tools enable researchers to simultaneously analyze RNA and proteins in thousands of individual cells and develop a more complete picture of the role genes and proteins play in biological systems.
Initially available with more than 100 different human antibody-oligonucleotide combinations, over time BD will expand the portfolio to utilise its library of flow cytometry-proven human and mouse antibody clones, helping researchers to advance understanding of complex diseases.
These new offerings provide targeted RNA-seq options and enable sample pooling to improve data quality and reduce time to discovery.
BD develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products worldwide.
The company provides solutions that help advance medical research and genomics, enhance the diagnosis of infectious disease and cancer, improve medication management, promote infection prevention, equip surgical and interventional procedures, and support the management of diabetes.